BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Relmada Therapeutics Inc. – Underwriting Agreements

NASDAQ: RLMD    
Share price (10/2/26): $3.60    
Market cap (10/2/26): $384 million
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1
from SCHEDULE 13G/A Underwriting agreement
12/34/56
EX-1
from SCHEDULE 13G 1 page Joint Filing Agreement
12/34/56
EX-1
from SCHEDULE 13G/A Underwriting agreement
12/34/56
EX-1.1
from 8-K 39 pages 40,142,000 Shares and Pre-Funded Warrants to Purchase 5,315,000 Shares Relmada Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1
from SCHEDULE 13G/A Underwriting agreement
12/34/56
EX-1
from SCHEDULE 13G Underwriting agreement
12/34/56
EX-1.2
from S-3ASR 38 pages Relmada Therapeutics, Inc., a Nevada Corporation (The “Company”), Proposes, Subject to the Terms and Conditions Stated Herein, to Issue and Sell From Time to Time Through Jefferies LLC, as Sales Agent and/or Principal (The “Agent”), Shares of the Company’s Common Stock, Par Value $0.001 Per Share (The “Common Shares”), on the Terms Set Forth in This Agreement (This “Agreement”). Section 1. Definitions (A) Certain Definitions. for Purposes of This Agreement, Capitalized Terms Used Herein and Not Otherwise Defined Shall Have the Following Respective Meanings
12/34/56
EX-1.1
from 8-K 30 pages 8,823,530 Shares Relmada Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1
from SC 13G/A ~1 page Joint Filing Statement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from 8-K 39 pages 3,333,334 Shares Relmada Therapeutics, Inc. Underwriting Agreement
12/34/56
EX-1.2
from S-3 45 pages Relmada Therapeutics, Inc. Shares of Common Stock (Par Value $0.001 Per Share) Controlled Equity Offeringsm Sales Agreement
12/34/56